ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 208.93M shares outstanding
USProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates.
It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract.
The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Alan M. Lotvin, M.D.
Director
Brian J.G. Pereira, M.D.
Director
Bruce Culleton, M.D.
Chief Executive Officer and Director
Jennifer Fox
Director
Employees
204
Country
US
Sector
Healthcare
Website
prokidney.com
Loading congressional disclosures…
based on 208.93M shares outstanding
US30d Avg
1.69M
60d Avg
1.42M
90d Avg
1.29M
